Definitive Healthcare Corp.

Annual Trend FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Depreciation and amortization $1.2m $1.8m $2.2m $2.0m $2.2m $3.3m
Amortization of intangible assets $58.4m $58.2m $54.7m $49.8m $49.4m $52.8m
Amortization of deferred contract costs $1.7m $4.8m $8.8m $13.0m $15.4m $15.9m
Amortization of debt issuance costs $2.1m $1.7m $702k $702k $702k $519k
Deferred income taxes $0 $682k ($17.3m) ($18.7m) ($42.7m) ($10.9m)
Goodwill impairment charges $0 $0 $287.4m $688.9m $196.1m
Loss on partial extinguishment of debt $0 $0 $507k
Net loss ($51.2m) ($61.3m) ($22.3m) ($289.6m) ($591.4m) ($199.3m)
Equity-based compensation $1.7m $10.0m $36.4m $48.7m $38.1m $29.1m
Write-off of deferred offering costs $0 $0 $467k
(Recovery of) provision for bad debt expense $1.3m $1.4m $947k ($232k)
Non-cash restructuring charges $1.0m $155k $1.2m $595k
TRA remeasurement $0 $0 ($9.4m) ($23.5m) ($76.9m) ($21.7m)
Changes in fair value of contingent consideration $2.6m $3.8m $1.2m $302k ($1.8m) ($4.0m)
Accounts receivable ($8.3m) ($10.7m) ($13.2m) $811k $5.7m $1.4m
Prepaid expenses and other assets ($709k) ($3.7m) ($127k) ($7.2m) ($7.8m) ($2.2m)
Deferred contract costs ($7.7m) ($14.4m) ($15.3m) ($18.8m) ($12.8m) ($13.4m)
Contingent consideration ($2.6m) $0 ($1.0m) ($7.8m) ($602k) $0
Accounts payable, accrued expenses and other liabilities $3.0m $1.1m $358k $1.3m ($5.5m) ($1.1m)
Deferred revenue $12.1m $23.0m $12.7m ($6.6m) ($5.0m) $5.9m
Purchases of property, equipment and other assets ($1.4m) ($6.7m) ($8.3m) ($3.0m) ($12.3m) ($16.7m)
Repayments of term loans ($6.9m) ($8.6m) ($13.8m) ($252.8m)
Proceeds from term loan $0 $275.0m $0 $0 $0 $175.0m
Payments of contingent consideration $0 ($1.5m) ($1.1m) $0 ($1.0m) $0
Payments under TRA $0 $0 ($246k) ($7.0m) ($13.8m)
Payments of equity offering issuance costs $0 ($11.7m) ($1.7m) ($30k) $0 $0
Member distributions ($2.9m) ($8.1m) ($12.9m) ($12.3m) ($5.1m) ($3.1m)
Interest $26.0m $29.6m $10.4m $14.5m $14.2m $10.8m
Income taxes $0 $13k $0 $136k $0 $833k
Net assets acquired, net of cash acquired $43.6m $0 $97.3m $52.7m $13.7m $0
Working capital adjustment receivable $0 $0 $145k ($145k) $0
Net cash paid for acquisitions $22.5m $0 $56.3m $45.0m $13.5m $0
Capital expenditures included in accounts payable and accrued expenses and other liabilities $3.4m $654k $1.2m $47k $6.9m $4.5m
Unpaid equity offering costs included in accrued expenses $0 $1.3m $0 $0
Net cash provided by operating activities $23.2m $25.2m $35.6m $41.2m $58.2m $53.8m
Purchases of short-term investments $0 $0 ($338.0m) ($259.2m) ($304.3m) ($64.1m)
Cash paid for acquisitions and investments, net of cash acquired ($22.5m) ($40.0m) ($56.3m) ($45.0m) ($13.5m) $0
Maturities of short-term investments $0 $0 $153.7m $275.4m $303.8m $234.7m
Net cash provided by (used in) investing activities ($23.9m) ($46.7m) ($248.9m) ($31.8m) ($26.4m) $153.9m
Payments of debt issuance costs ($225k) ($3.5m) $0 $0 $0 ($1.7m)
Repurchases of Class A common stock $0 $0 ($22.4m) ($49.5m)
Net cash used in financing activities $16.7m $384.4m ($26.7m) ($25.6m) ($56.7m) ($150.8m)
Effect of exchange rate changes on cash and cash equivalents $146k ($129k) ($544k) $218k ($636k) $1.4m
Net increase (decrease) in cash and cash equivalents $16.0m $362.9m ($240.0m) ($16.2m) ($25.0m) $56.9m
Cash and cash equivalents, beginning of year $24.8m $387.5m $146.9m $131.0m $105.4m $163.6m
Taxes paid related to net share settlement of equity awards $0 $0 ($4.1m) ($4.4m) ($7.5m) ($4.9m)